Increased case-finding and uptake of direct-acting antiviral treatment essential for micro-elimination of hepatitis C among people living with HIV : a national record linkage study
© 2020 British HIV Association..
OBJECTIVES: Micro-elimination of hepatitis C virus (HCV) in people living with HIV (PLHIV) and co-infected with HCV has been proposed as a key contribution to the overall goal of HCV elimination. While other studies have examined micro-elimination in HIV-treated cohorts, few have considered HCV micro-elimination among those not treated for HIV or at a national level.
METHODS: Through data linkage of national and sentinel surveillance data, we examined the extent of HCV testing, diagnosis and treatment among a cohort of PLHIV in Scotland identified through the national database of HIV-diagnosed individuals, up to the end of 2017.
RESULTS: Of 5018 PLHIV, an estimated 797 (15%) had never been tested for HCV and 70 (9%) of these had undiagnosed chronic HCV. The odds of never having been tested for HCV were the highest in those not on HIV treatment [adjusted odds ratio (aOR) = 7.21, 95% confidence interval (CI): 5.15-10.10). Overall HCV antibody positivity was 11%, and it was at its highest among people who inject drugs (49%). Most of those with chronic HCV (91%) had attended an HCV treatment clinic but only half had been successfully treated (54% for those on HIV treatment, 12% for those not) by the end of 2017. The odds of never having been treated for HCV were the highest in those not on HIV treatment (aOR = 3.60, 95% CI: 1.59-8.15).
CONCLUSIONS: Our data demonstrate that micro-elimination of HCV in PLHIV is achievable but progress will require increased effort to engage and treat those co-infected, including those not being treated for their HIV.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
---|---|
Enthalten in: |
HIV medicine - 22(2021), 5 vom: 22. Mai, Seite 334-345 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
McLeod, A [VerfasserIn] |
---|
Links: |
---|
Themen: |
Antiviral Agents |
---|
Anmerkungen: |
Date Completed 14.03.2022 Date Revised 14.03.2022 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1111/hiv.13032 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM319146669 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM319146669 | ||
003 | DE-627 | ||
005 | 20231225170831.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1111/hiv.13032 |2 doi | |
028 | 5 | 2 | |a pubmed24n1063.xml |
035 | |a (DE-627)NLM319146669 | ||
035 | |a (NLM)33350049 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a McLeod, A |e verfasserin |4 aut | |
245 | 1 | 0 | |a Increased case-finding and uptake of direct-acting antiviral treatment essential for micro-elimination of hepatitis C among people living with HIV |b a national record linkage study |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 14.03.2022 | ||
500 | |a Date Revised 14.03.2022 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2020 British HIV Association. | ||
520 | |a OBJECTIVES: Micro-elimination of hepatitis C virus (HCV) in people living with HIV (PLHIV) and co-infected with HCV has been proposed as a key contribution to the overall goal of HCV elimination. While other studies have examined micro-elimination in HIV-treated cohorts, few have considered HCV micro-elimination among those not treated for HIV or at a national level | ||
520 | |a METHODS: Through data linkage of national and sentinel surveillance data, we examined the extent of HCV testing, diagnosis and treatment among a cohort of PLHIV in Scotland identified through the national database of HIV-diagnosed individuals, up to the end of 2017 | ||
520 | |a RESULTS: Of 5018 PLHIV, an estimated 797 (15%) had never been tested for HCV and 70 (9%) of these had undiagnosed chronic HCV. The odds of never having been tested for HCV were the highest in those not on HIV treatment [adjusted odds ratio (aOR) = 7.21, 95% confidence interval (CI): 5.15-10.10). Overall HCV antibody positivity was 11%, and it was at its highest among people who inject drugs (49%). Most of those with chronic HCV (91%) had attended an HCV treatment clinic but only half had been successfully treated (54% for those on HIV treatment, 12% for those not) by the end of 2017. The odds of never having been treated for HCV were the highest in those not on HIV treatment (aOR = 3.60, 95% CI: 1.59-8.15) | ||
520 | |a CONCLUSIONS: Our data demonstrate that micro-elimination of HCV in PLHIV is achievable but progress will require increased effort to engage and treat those co-infected, including those not being treated for their HIV | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a HIV | |
650 | 4 | |a elimination | |
650 | 4 | |a hepatitis C | |
650 | 4 | |a micro-elimination | |
650 | 4 | |a record linkage | |
650 | 4 | |a surveillance | |
650 | 7 | |a Antiviral Agents |2 NLM | |
700 | 1 | |a Hutchinson, S J |e verfasserin |4 aut | |
700 | 1 | |a Smith, S |e verfasserin |4 aut | |
700 | 1 | |a Leen, C |e verfasserin |4 aut | |
700 | 1 | |a Clifford, S |e verfasserin |4 aut | |
700 | 1 | |a McAuley, A |e verfasserin |4 aut | |
700 | 1 | |a Wallace, L A |e verfasserin |4 aut | |
700 | 1 | |a Barclay, S T |e verfasserin |4 aut | |
700 | 1 | |a Bramley, P |e verfasserin |4 aut | |
700 | 1 | |a Dillon, J F |e verfasserin |4 aut | |
700 | 1 | |a Fraser, A |e verfasserin |4 aut | |
700 | 1 | |a Gunson, R N |e verfasserin |4 aut | |
700 | 1 | |a Hayes, P C |e verfasserin |4 aut | |
700 | 1 | |a Kennedy, N |e verfasserin |4 aut | |
700 | 1 | |a Peters, E |e verfasserin |4 aut | |
700 | 1 | |a Templeton, K |e verfasserin |4 aut | |
700 | 1 | |a Goldberg, D J |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t HIV medicine |d 1999 |g 22(2021), 5 vom: 22. Mai, Seite 334-345 |w (DE-627)NLM116282541 |x 1468-1293 |7 nnns |
773 | 1 | 8 | |g volume:22 |g year:2021 |g number:5 |g day:22 |g month:05 |g pages:334-345 |
856 | 4 | 0 | |u http://dx.doi.org/10.1111/hiv.13032 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 22 |j 2021 |e 5 |b 22 |c 05 |h 334-345 |